Pemigatinib 4.5 mg, 9 mg, 13.5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 4.5 mg, 9 mg, 13.5 mg

Reference Brands: Pemazyre (USA/EU)

Category: Oncology Cancer Care

Pemigatinib is a Oncology Cancer Care product available as Tablets in strengths 4.5 mg, 9 mg, 13.5 mg. It corresponds to the reference brand Pemazyre (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Pemigatinib, marketed under the brand name Pemazyre, is an orally bioavailable small-molecule inhibitor of fibroblast growth factor receptors 1, 2, and 3 (FGFR1/2/3) with antineoplastic activity. It belongs to the class of protein kinase inhibitors and specifically targets FGFRs, which are receptor tyrosine kinases expressed on the surface of certain cancer cells. These receptors play a critical role in cell proliferation, migration, and survival, and are often upregulated in various tumor types.

By binding to and inhibiting FGFR1/2/3, pemigatinib blocks downstream signal transduction pathways that promote tumor cell growth and proliferation. This mechanism effectively suppresses the growth of FGFR-overexpressing tumor cells and helps prevent cancer progression.

Clinically, pemigatinib is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma (bile duct cancer) who harbor FGFR2 fusions or rearrangements and have received prior therapy. Administered orally in tablet form, pemigatinib provides a targeted therapeutic approach, offering a promising option for patients with FGFR-driven cancers. Its selective inhibition of FGFRs contributes to tumor growth control while minimizing effects on non-target cells, making it an important addition to modern oncology care.